Drug Trial Radar · NCT05141994
Clinical Study on the Efficacy and Safety of BAT5906 Injection
Last checked: Nov 19, 2026Latest source record: Apr 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Aug 26, 2020
Primary completion
Sep 6, 2022
Study completion Sep 6, 2022
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, open, and phase II clinical study to evaluate the efficacy and safety of BAT5906 injection in patients with wet age-related macular degeneration. The results of the BAT5906 Phase I study show that it is safe from 0.3-4.0 mg, and that higher doses (2.5 mg and 4 mg) may be substituted for the duration of maintenance efficacy; drugs with the same target (such as brolucizumab and Abecip) have also been found in clinical studies High doses can extend the interval and reduce the frequency of administration. Therefore, in this study, two doses with better safety and efficacy were selected, once every 4 weeks, followed by 3 consecutive injections for treatment as needed, and preliminary exploration of the best clinical effective dose and replacement frequency
Conditions
- Wet Age-related Macular Degeneration
Interventions
2.5mg of BAT5906Drug
Specification: 2.5mg of BAT5906
4mg of BAT5906Drug
Specification: 4mg of BAT5906
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-response relationshipsTime frame: week 24
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Eye Hospital of China Academy of Chinese Medical Sciences
Beijing, China
Peking University First Hospital
Beijing, China
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Zhejiang Provincial People's Hospital
Hangzhou, China
Jieyang People's Hospital
Jieyang, China
The First Hospital of Jilin University
Jilin City, China
he Affiliated Eye Hospital of Nanchang University
Nanchang, China
Jiangsu Provincial Hospital of Traditional Chinese Medicine
Nanjing, China
The Affiliated Hospital of Qingdao University
Qingdao, China
Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong
Shantou, China
West China Hospital of Sichuan University
Sichuan, China
Wenzhou Medical University Affiliated Optometry Hospital
Wenzhou, China
The Second Xiangya Hospital of Central South University
Xiangya, China
Henan Provincial Eye Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.